Directly from ESC 2024 - Kausik Ray, MD, MPhil: INTERASPIRE and the Expanding Knowledge Base for Lipoprotein(a)
Few topics or biomarkers have garnered the same amount of attention for their association with cardiovascular risk in recent years as lipoprotein(a) [Lp(a)]. This trend continued at the European Society of Cardiology (ESC) Congress 2024, as the cardiology community and lipidologists had their knowledge on the topic expanded through the presentation of novel data, including the INTERASPIRE study, which was presented by Kausik Ray, MD, MPhil, professor of Public Heath, director of the Imperial Centre for CVD Prevention, deputy director of Imperial Clinical Trials Unit and head of Commercial Trials at Imperial College London.
An international survey designed to assess Lp(a) levels in patients recently diagnosed with coronary heart disease across multiple countries and regions, INTERASPIRE leveraged data from 13 countries, including information related to testing methodologies, patient interviews and central lab analyses. The study’s primary objectives were to determine how elevated Lp(a) is in patients with recent coronary heart disease across 6 World Health Organization regions, assessing variation between countries within these regions, and drawing inferences about ongoing and future clinical trials. The study also aimed to identify the determinants of Lp(a) levels in a global coronary heart disease population and to explore the extent to which lifestyle and risk factor management can mitigate the risks associated with high Lp(a) levels.
To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.
Source: MDMag
